BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors von Rhyasen, Garrett W, Yao, Yi, Zhang, Jingwen, Dulak, Austin, Castriotta, Lillian, Jacques, Kelly, Zhao, Wei, Gharahdaghi, Farzin, Hattersley, Maureen M, Lyne, Paul D, Clark, Edwin, Zinda, Michael, Fawell, Stephen E, Mills, Gordon B, Chen, Huawei

Volltext

AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies von Rhyasen, Garrett W, Hattersley, Maureen M, Yao, Yi, Dulak, Austin, Wang, Wenxian, Petteruti, Philip, Dale, Ian L, Boiko, Scott, Cheung, Tony, Zhang, Jingwen, Wen, Shenghua, Castriotta, Lillian, Lawson, Deborah, Collins, Michael, Bao, Larry, Ahdesmaki, Miika J, Walker, Graeme, O'Connor, Greg, Yeh, Tammie C, Rabow, Alfred A, Dry, Jonathan R, Reimer, Corinne, Lyne, Paul, Mills, Gordon B, Fawell, Stephen E, Waring, Michael J, Zinda, Michael, Clark, Edwin, Chen, Huawei

Volltext

VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status von Bizzaro, Francesca, Fuso Nerini, Ilaria, Taylor, Molly A, Anastasia, Alessia, Russo, Massimo, Damia, Giovanna, Guffanti, Federica, Guana, Francesca, Ostano, Paola, Minoli, Lucia, Hattersley, Maureen M, Arnold, Stephanie, Ramos-Montoya, Antonio, Williamson, Stuart C, Galbiati, Alessandro, Urosevic, Jelena, Leo, Elisabetta, Cavallaro, Ugo, Ghilardi, Carmen, Barry, Simon T, Bani, Maria Rosa, Giavazzi, Raffaella

Volltext

The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cells von Criscione, Steven W., Martin, Matthew J., Oien, Derek B., Gorthi, Aparna, Miragaia, Ricardo J., Zhang, Jingwen, Chen, Huawei, Karl, Daniel L., Mendler, Kerrin, Markovets, Aleksandra, Gagrica, Sladjana, Delpuech, Oona, Dry, Jonathan R., Grondine, Michael, Hattersley, Maureen M., Urosevic, Jelena, Floc’h, Nicolas, Drew, Lisa, Yao, Yi, Smith, Paul D.

Volltext

Evaluating Chemical Mixtures in Epidemiological Studies to Inform Regulatory Decisions von Savitz, David A, Hattersley, Anne M

Volltext

The safety assessment of tampons: illustration of a comprehensive approach for four different products von Hochwalt, Anne E, Abbinante-Nissen, Joan M, Bohman, Lisa C, Hattersley, Anne M, Hu, Ping, Streicher-Scott, Jan L, Teufel, Amber G, Woeller, Kara E

Volltext

Support of adult urinary incontinence products: recommendations to assure safety and regulatory compliance through application of a risk assessment framework von Krause, Edburga L, Hattersley, Anne M, Abbinante-Nissen, Joan M, Gutshall, Denise, Woeller, Kara E

Volltext

Translational Modeling of Drug‐Induced Myelosuppression and Effect of Pretreatment Myelosuppression for AZD5153, a Selective BRD4 Inhibitor von Collins, TA, Hattersley, MM, Yates, JWT, Clark, E, Mondal, M, Mettetal, JT

Volltext

BRD4 facilitates replication stress-induced DNA damage response von Zhang, Jingwen, Dulak, Austin M., Hattersley, Maureen M., Willis, Brandon S., Nikkilä, Jenni, Wang, Anderson, Lau, Alan, Reimer, Corinne, Zinda, Michael, Fawell, Stephen E., Mills, Gordon B., Chen, Huawei

Volltext

Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors von Lim, Emerson A, Bendell, Johanna C, Falchook, Gerald S, Bauer, Todd M, Drake, Charles G, Choe, Jennifer H, George, Daniel J, Karlix, Janet L, Ulahannan, Susanna, Sachsenmeier, Kris F, Russell, Deanna L, Moorthy, Ganesh, Sidders, Ben S, Pilling, Elizabeth A, Chen, Huifang, Hattersley, Maureen M, Das, Mayukh, Kumar, Rakesh, Pouliot, Gayle P, Patel, Manish R

Volltext

Assessment of adverse events for a home‐use intense pulsed light hair removal device using postmarketing surveillance von Hattersley, Anne M., Kiernan, Michael, Goldberg, David, Dierickx, Christine, Sliney, David H., Haedersdal, Merete, Nash, J. Frank

Volltext

First-in-Human Study of AZD5153, A Small Molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma von Hamilton, Erika P, Wang, Judy S, Oza, Amit M, Patel, Manish R, Ulahannan, Susanna V, Bauer, Todd, Karlix, Janet L, Zeron-Medina, Jorge, Fabbri, Giulia, Marco-Casanova, Paola, Moorthy, Ganesh, Hattersley, Maureen M, Littlewood, Gillian M, Mitchell, Patrick D, Saeh, Jamal, Pouliot, Gayle P, Moore, Kathleen N

Volltext

Bromodomain and extra-terminal inhibitors—A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children—ACCEL... von Pearson, Andrew DJ, DuBois, Steven G., Buenger, Vickie, Kieran, Mark, Stegmaier, Kimberly, Bandopadhayay, Pratiti, Bennett, Kelly, Bourdeaut, Franck, Brown, Patrick A., Chesler, Louis, Clymer, Jessica, Fox, Elizabeth, French, Christopher A., Germovsek, Eva, Giles, Francis J., Bender, Julia G., Hattersley, Maureen M., Ludwinski, Donna, Luptakova, Katarina, Maris, John, McDonough, Joe, Nikolova, Zariana, Smith, Malcolm, Tsiatis, Athanasios C., Vibhakar, Rajeev, Weiner, Susan, Yi, Joanna S., Zheng, Fred, Vassal, Gilles

Volltext

A phase 2 study of AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancer von Falchook, Gerald S., Reeves, James, Gandhi, Sunil, Spigel, David R., Arrowsmith, Edward, George, Daniel J., Karlix, Janet, Pouliot, Gayle, Hattersley, Maureen M., Gangl, Eric T., James, Gareth D., Thompson, Jeff, Russell, Deanna L., Patel, Bhavickumar, Kumar, Rakesh, Lim, Emerson

Volltext

BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in Kras -Mutant Non-Small Cell Lung Cancer von Adeegbe, Dennis O, Liu, Shengwu, Hattersley, Maureen M, Bowden, Michaela, Zhou, Chensheng W, Li, Shuai, Vlahos, Raven, Grondine, Michael, Dolgalev, Igor, Ivanova, Elena V, Quinn, Max M, Gao, Peng, Hammerman, Peter S, Bradner, James E, Diehl, J Alan, Rustgi, Anil K, Bass, Adam J, Tsirigos, Aristotelis, Freeman, Gordon J, Chen, Huawei, Wong, Kwok-Kin

Volltext

403 AZD1480 is a Potent Inhibitor of ROS1 and Induces Regression in ROS1 Fusion Containing Cancer Models von Drew, L, Shen, M, Patterson, T, Cheung, T, Hattersley, M, Hennessy, E, Guan, N, Denz, C, Scarpitti, M, McCoon, P

Volltext

Heteroarylamide smoothened inhibitors: Discovery of N-[2,4-dimethyl-5-(1-methylimidazol-4-yl)phenyl]-4-(2-pyridylmethoxy)benzamide (AZD8542) and N-[5-(1H-imidazol-2-yl)-2,4-dimethy... von Yang, Bin, Hird, Alexander W., Bodnarchuk, Michael S., Zheng, Xiaolan, Dakin, Les, Su, Qibin, Daly, Kevin, Godin, Robert, Hattersley, Maureen M., Brassil, Patrick, Redmond, Sean, John Russell, Daniel, Janetka, James W.

Volltext

BET inhibition targets ABC-DLBCL constitutive B-cell receptor signaling through PAX5 von Oien, Derek B., Sharma, Samanta, Hattersley, Maureen M., DuPont, Michelle, Criscione, Steven W., Prickett, Laura, Goeppert, Anne U., Drew, Lisa, Yao, Yi, Zhang, Jingwen, Chan, Ho Man

Volltext

Development of a microfluidic device for the maintenance and interrogation of viable tissue biopsies von Hattersley, Samantha M, Dyer, Charlotte E, Greenman, John, Haswell, Stephen J

Volltext

Study of ethanol induced toxicity in liver explants using microfluidic devices von Hattersley, Samantha M., Greenman, John, Haswell, Stephen John

Volltext